The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages ...

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

This is to inform you that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control ...

Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.

If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...

The company has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution ...

AstraZeneca Plc’s Imfinzi extended the lives of patients with bladder cancer, potentially opening up a new market for the ...

Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...

The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by ...